ARPO Aerpio Pharmaceuticals Inc

DGAP-News: MC Services to support BIO-Europe 2018 as media partner

DGAP-News: MC Services AG / Key word(s): Conference
MC Services to support BIO-Europe 2018 as media partner

31.10.2018 / 13:53
The issuer is solely responsible for the content of this announcement.


Press Release
31 October 2018

MC Services to support BIO-Europe 2018 as media partner

Munich/Düsseldorf, Germany, 31 October 2018. MC Services AG, an international public relations and investor relations firm, announced today that it will support, as a media partner, the 24th annual , Europe's largest partnering conference for the global biotechnology industry. The event, organized by EBD Group, will take place from 5-7 November 2018 at the Bella Center in Copenhagen, Denmark.

As a media partner, MC Services invited local and international journalists to attend the event and provided them with information on presenting companies, their executives and investors. MC Services will be on site throughout the conference, conducting both media and partnering meetings.

"In a world of increasing globalization, partnerships are a key to success for the life sciences sector; an industry driven by innovation", said Anne Hennecke, Managing Partner of MC Services. "BIO-Europe 2018 gathers industry leaders seeking collaborations through strategic partnerships in order to drive the evolution of healthcare developments. That is why MC Services is excited to once again support this partnering event, promoting international awareness and fostering media relations".

Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic partnerships that support the successful growth of their businesses. Last year over 24,000 one-to-one partnering meetings were held. This year's event is expected to draw over 4,000 industry attendees from over 60 countries, representing more than 2,100 companies for three days of high-level networking. Furthermore, reputable speakers will share their expertise and views on how geopolitics are affecting the future of biopharma, SME funding, gene and cell therapies, how to ink the deal, orphan drug development and more. For detailed information regarding the program, timing and location, please visit the event's .

# # #

Additional links and information:

Follow BIO-Europe 2018 on Twitter: (hashtag: #BIOEUROPE).

About MC Services AG
MC Services AG is an international public relations and investor relations firm specializing in communications for the life sciences and healthcare sector. A strong team of science, finance, media and communication experts with extensive industry experience positions MC Services as a leading life sciences agency in Europe. MC Services' long-standing clients include international public and private companies, as well as venture capitalists and investment firms. Established for many years as a link between the healthcare industry and the financial markets, MC Services provides comprehensive services in investor relations, public relations and financial transactions. MC Services is based in Munich, Düsseldorf, London and Boston.

About BIO-Europe
BIO-Europe is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing upwards of 2,000 companies from over 60 countries. To learn more about the conference, please visit /bioeurope/.

Contact:
Anne Hennecke
MC Services AG
T 22
Email:

 



31.10.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


739969  31.10.2018 

fncls.ssp?fn=show_t_gif&application_id=739969&application_name=news&site_id=research_pool
EN
31/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch